Bacteriophages to outsmart
antibiotic-resistant infections
Nearly 5 million deaths are associated each year with antibiotic-resistant infections. Bacterial resistance is rising.
Treatment options are running out.
We’re here to change that.
Antimicrobial Resistance (AMR)
According to the WHO, AMR is one of the most pressing global health challenges of our time, already causing an estimated 4.95 million deaths each year. Alarmingly, one in six bacteria is now resistant to the antibiotics most commonly used in clinical practice, and the burden of resistance has increased by 40% over the past five years alone. If no effective action is taken, AMR-related deaths are projected to reach 10 million per year by 2050.
Among the most dangerous contributors to this crisis are the so-called ESKAPE pathogens, which are responsible for the majority of severe infections and are increasingly difficult and sometimes even impossible to treat. At Inteliphage, we want to break this cycle!
Building the pathway from diagnosis to treatment planning
Effective phage therapy begins with selecting the right bacteriophage for each patient's infection. Inteliphage is developing PhageXpert™, an automated phage susceptibility (phagogram) workflow combining a kit and software, enabling timely and informed treatment decisions.
In parallel, we are building a high-quality phage supply capability and curated phage library to enable access to appropriate therapeutic phage candidates through applicable clinical and regulatory pathways. By combining an automated selection workflow with clinical expertise, Inteliphage aims to support teams across the full phage therapy pathway.
Transforming lives by enabling accessible, personalized and adaptive phage therapy for health professionals treating
the hardest bacterial infections
OUR MISSION
Our Vision
Our vision is a world where bacterial infections remain treatable. Today, millions of people die each year from infections that no longer respond to antibiotics and many more live with the long-term burden of chronic infection. As resistance rises, antibiotics are failing and new options aren’t keeping pace.
At Inteliphage, we fight bacteria on their own turf by harnessing their natural enemies: bacteriophages. By combining personalized phage therapy with advanced diagnostics and decision-support tools, we aim to help clinicians treat difficult-to-treat infections and offer patients new hope when standard care falls short.
LEARN MORE
The latest from Inteliphage
09/12/2025
Inteliphage joins BEAM Alliance
We're happy to share that Inteliphage has joined the BEAM Alliance, the European AMR innovation hub bringing together SMEs & biotech companies to tackle antimicrobial resistance, turning innovations into real treatments.
12/11/2025
Inteliphage joins Future4Care
We’re excited to share that Inteliphage has joined Future4Care, a vibrant European ecosystem of healthtech innovators building the healthcare systems of the future.
12/08/2025
New name, same mission, bigger ambition
After five years of growth, discovery and collaboration, Vésale Bioscience is now Inteliphage. Why the change?
Information on this website may describe products, technologies and capabilities that are in development and not CE-marked and/or not yet authorised for clinical use or commercial supply in the EU. This content is provided for scientific and corporate information purposes only and does not constitute an offer for sale, medical advice or instructions for clinical use.